P464 Infliximab optimisation in ulcerative colitis: Intensificated and deintensificated patients clinical outcome

after induction) but they were stopped in 42%, 13 (0 48) months after IFX induction. IFX treatment was intensificated in 40% (10% doubling dose, 60% shortening intervales, 30% both). 43% of intensificated patients were deintensificated, but 23% of them were reintensificated. Steroids were reintroduced in 38%. 44% of patients had IFX stopped (20% because of no response, 39% because of loss of response after 11 (3 65) months, 31% because of AE and 10% because of prolonged remission). AEs were infusional reactions in 28% and severe infections in 28%. From IFX induction to end of follow up [42 (1 122) months] 20% of patients had a colectomy. Conclusions: 56% of patients mantain response to IFX after 42 (SD 27) months from IFX induction. In 44% of patients IFX treatment is stopped because of loss or no response and adverse events mainly. Cotreatment with immunosuppressants and intensification seems to be useful strategies in the management of these patients and are regularly used.